Clinical trials
Phase 3 Diabetes Mellitus trials in Mexico
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
93 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 6 |
| 2005 | 1 |
| 2006 | 11 |
| 2007 | 6 |
| 2008 | 9 |
| 2009 | 9 |
| 2010 | 5 |
| 2011 | 7 |
| 2012 | 2 |
| 2013 | 6 |
| 2014 | 5 |
| 2015 | 2 |
| 2016 | 5 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2024 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 82 |
| Terminated | 7 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novo Nordisk A/S | 26 |
| AstraZeneca | 20 |
| Eli Lilly and Company | 12 |
| Takeda | 10 |
| Daiichi Sankyo | 4 |
| Allergan | 3 |
| GlaxoSmithKline | 3 |
| Janssen Research & Development, LLC | 3 |
| Bristol-Myers Squibb | 2 |
| Pfizer | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus | 93 |
| Diabetes Mellitus, Type 2 | 77 |
| Glucose Metabolism Disorders | 18 |
| Metabolic Diseases | 11 |
| Endocrine System Diseases | 9 |
| Dyslipidemias | 8 |
| Gastroparesis | 3 |
| Insulin Resistance | 3 |
| Cardiovascular Diseases | 2 |
| Diabetes Mellitus, Lipoatrophic | 2 |
Trials
Showing 1 to 25 of 93. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.